Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Poster Exhibitions

Tuesday lulv Q. - - - - - 7 IF - -7 If

Tuesday

TuPeB4627 Experience in resistance testing guided treatment
in HIV-1 infected children under therapeutic
failure. Long term follow-up
S Lopez Papucci, M C Campodonico, M S Benetti,
F F Fay, C Martearena, E Perez Hernandez, 0 H Fay
(Argentina)
TuPeB4628 Impact of kaletra treatment in HIV-infected Children
M M Castrejon, E Castano, 0 Suman, ] Nieto,
] M Sanchez-Granados, M I Gonzalez-Tome,
X Saez-Llorens (Panama)
TuPeB4629 Hyperbilirubinemia in children treated with
Indinavir
FE Eseme C Giaquinto, E Ruga, 0 Rampon, A De
Rossi, V Giacomet, M Sturkenboom, C Manzardo,
F Fregonese, V Balasso, F Ebo, R D'Elia (Italy)
TuPeB463o Treatment interruptions of HAART in paediatric
HIV: effect on CD4 count
V Lecleziol, T Duong', L McGee', N Martinez-Alier',
D M Gibb', G Verwee2P (United Kingdom; 2The
Netherlands)
TuPeB4631 CD4 and HIV RNA response following HAART in
ART naive children
A S Walker', D M Gibb', L McGee', D Dunn',
G Tudor-Williams', M Sharland', K Butler2,
V Novelli ('United Kingdom; 2Ireland)
TuPeB4632 Pharmacokinetics and safety of 2 mg/kg T-2o in
combination therapy in HIV infected children and
adolescents
S E Bellibas', T Pepper, A Dorr', A Bertasso',
P Sista', F Duff1, S ]Kolis', P DeLora*1
(United States; 2United Kingdom)
TuPeB4633 Virologic failure in HIV-infected children treated
with efavirenz (EFV), nelfinavir (NFV) and
nucleoside reverse transcriptase inhibitors
(NRTIs) is frequently associated with resistance
to efavirenz but uncommonly to nelfinavir
S A Sector K Hsia, T Fenton, S Cabral,
CA Powell, C V Fletcher, SE Starr (United States)
TuPeB4634 Antiretroviral efficacy and tolerability of Abacavir
(ABC) based regimens in a clinical cohort of HIVinfected children
F Hoffmann, T Niehues, B Buchholz, C Engelhorn
S Urschel, G Notheis, B H Belohradsky,
U H P Wintergerst (Germany)
TuPeB4635 Lipodystrophy syndrome in HIV-infected children
M ]Mellado, ] Villota, M Garcia, M L Perez,
S Perez, ] Almazdn, M ] Cilleruelo, P MartinFontelos (Spain)
TuPeB4636 Efavirenz-based antiretroviral combination
therapy for the firstline-treatment of HIV-infected
children
C Engelhorn, F Hoffmann, S Urschel, G Notheis,
B H Belohradsky, U H P Wintergerst (Germany)
TuPeB4637 Efficacy and safety of
Ritonavir+Saquinavir+d4T+ddl versus
nelfinavir+Efavirenz+d4T+ddl in H IV-infected
children with prior antiretroviral exposure
M E Nand[ Lozano, C Avila Figueroa, ]] Morales
Aguirre (Mexico)
TuPeB4638 Assessment of bone strength in children with
HIV/AIDS on HAART using a novel non-invasive
bone ultrasound
N Desai, M Mathur (United States)
TuPeB4639 Highly active antiretroviral regimens initiated in
infancy achieve viral suppression, but failure to
suppress viral loads promotes early antiretroviral
resistance

D H Conway, ]IS Chen, M L Bagarazzi, ]A Foster
(United States)

TuPeB464o The efficacy of triple therapy without PI in HIV
infected children
A M Tudor M Dragan, M Mardarescu, S Petrea
(Romania)
TuPeB4641 Multidisciplinary approach to be able to provide
holistic care for the orphans
P Manorama, VS Valavan (India)
TuPeB4642 Clinical value of HIV-1 genotyping in children and
adolescents heavily experienced in antiretroviral
therapy (ART)
N PM Rubini', PA Brindeiro', R M Brindeiro',
CA Llerena', K Hertogs2, A Tanuri', FS Sion',
CA Morais-de-Sd' ('Brazil; 2Belgium)
TuPeB4643 Cost of antiretrovirals for HIV infected Ugandan
children
B O'Hare', P Musoke2 ('United Kingdom;
2Uganda)
TuPeB4644 Discontinuation of antiretroviral therapy in
children with perinatal HIV-infection
M Vocks-Hauck, M L Machler, B Schmidt
(Germany)
TuPeB4645 Effectiveness of dual and triple treatment
regimens in HIV-infected children in Belo
Horizonte, Brazil
R M C Romanelli L ] Melo, MA Vasconcelos,
R M Pereira, ]A Pinto (Brazil)
TuPeB4646 Evaluation of cellular immune responses to
Highly active antiretroviral therapy in HIV infected
children
R Claeys, ]] Calvin, ] C Bocanera, S Villalba
(Argentina)
TuPeB4647 Progressive harmful changes in body
composition are associated with increased
exposure to highly active antiretroviral therapy in
HIV-infected children
A Vigano' S Mora, S Beccio, C Testolin, D Bricalli,
A Vanzulli, P Brambilla (Italy)
TuPeB4648 Analysis of treatment and genotypic variation of
clade B and non-B HIV-1 in pediatric antiretroviral
therapy failure.
PA B Brindeiro R M Brindeiro, C Mortensen,
N PM Rubini, CA M de Sd, A Tanuri (Brazil)
TuPeB4649 Mitochondrial toxicity in HIV-infected pediatric
patients under antiretroviral treatment
A Noguera, B Perez-Duenas, L Martinez, L M Tello,
MA Vilaseca, C Fortuny (Spain)
TuPeB465o Emotional challenges of children infected/
affected by HIV/AIDS in children attending the
paediatric iss clinic in Mulago hospital
K E Ojambo E Barungi (Uganda)
TuPeB4651 The effect on triglyceride and cholesterol levels
after switching from a PI-based antiretroviral
regimen to a PI-sparing non nucleoside reverse
transcriptase (NNRTI)-based antiretroviral
therapy in HIV-infected children
G Notheis, F Hoffmann, C Engelhorn, A Iansson,
U Wintergerst, B H Belohradsky (Germany)
TuPeB4652 Mitochondrial toxicity in HIV-infected children on
antiretroviral therapy
M / Mellado, P Martin-Fontelos, R Polo, ] Villota,
M Garcfa, M L Perez, P Madrigal, S Martinez,
M Gonzalez-Mui'oz (Spain)
TuPeB4653 Prevalence evolution of genotipic resistance to
antiretroviral drugs in pre-treated HIV-i infected
children
C Munoz-Almagro, C Fortuny, T Puig, L Ruiz,
L Zamora, A Gonzalez-Cuevas, C Latorre (Spain)

102 Final Program